Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 14/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575794 | 0.89 | OGA (0.78) | OGA | |
| SCHEMBL20481982 | 0.88 | OGA (0.76) | OGA | |
| SCHEMBL23575779 | 0.85 | OGA (0.71) | OGACHRM2CHRM1 | |
| SCHEMBL21764478 | 0.84 | OGA (0.75) | OGAPOLBTP53CHRM2CHRM1 | |
| SCHEMBL23575754 | 0.80 | OGA (0.69) | OGA | |
| SCHEMBL20482206 | 0.79 | OGA (0.66) | OGA | |
| SCHEMBL20482123 | 0.75 | OGA (0.55) | OGA | |
| SCHEMBL20482016 | 0.75 | OGA (0.56) | OGA | |
| SCHEMBL21764674 | 0.75 | OGA (1.00) | OGA | |
| SCHEMBL23575525 | 0.75 | OGA (0.75) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841093-B1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11261183-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2022-03-01 | — | — | US | disclosed |
| US-20210198250-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | OGA 57/4885POLB 1376/4885TP53 3107/4885 |
| US-20210198250-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | SDHA, SDHB, SORD | OGA 614/4885POLB 951/4885TP53 1289/4885 |
| US-11261183-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | OGA 57/4885POLB 1376/4885TP53 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.